Pacira Biosciences, Inc. (PCRX)
Stock Price:
$61.22 USD
1.26 (2.10%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
2.62B |
| Revenue (ttm) |
408.30M |
| Net Income (ttm) |
-10.09M |
| Shares Out |
42.74M |
| EPS (ttm) |
-0.25 |
| PE Ratio |
n/a |
| Forward PE |
32.26 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$61.22 |
| Previous Close |
$59.96 |
| Change ($) |
1.26 |
| Change (%) |
2.10% |
| Day's Open |
60.36 |
| Day's Range |
59.81 - 61.29 |
| Day's Volume |
738,283 |
| 52-Week Range |
27.46 - 62.25 |
More Stats
| Market Cap |
2.62B |
| Enterprise Value |
2.69B |
| Earnings Date (est) |
Oct 28, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
42.74M |
| Float |
39.94M |
| EPS (basic) |
-0.25 |
| EPS (diluted) |
-0.25 |
| FCF / Share |
0.31 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
0.50% |
| Payout Ratio |
n/a |
| Shares Short |
6.50M |
| Short Ratio |
10.20 |
| Short % of Float |
27.01% |
| Beta |
1.28 |
| PE Ratio |
n/a |
| Forward PE |
32.26 |
| P/FCF Ratio |
199.40 |
| PS Ratio |
6.41 |
| PB Ratio |
6.43 |
| Revenue |
408.30M |
| Operating Income |
14.07M |
| Net Income |
-10.09M |
| Free Cash Flow |
13.12M |
| Net Cash |
-68.90M |
| Net Cash / Share |
-1.61 |
| Gross Margin |
59.32% |
| Operating Margin |
3.45% |
| Profit Margin |
-2.50% |
| FCF Margin |
3.21% |
| ROA |
2.45% |
| ROE |
-2.76% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (14)
| Buy |
9 |
| Overweight |
0 |
| Hold |
5 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$63.54*
(3.79% upside)
Low
54.0
Current: $61.22
High
85.0
Target: 63.54
*Average 12-month price target from 13 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 421 | 337 | 287 | 276 | 249 | 198 | 85.55 | 39.08 | 15.69 | 14.56 |
| Revenue Growth | 24.83% | 17.67% | 3.71% | 10.99% | 25.97% | 131.05% | 118.89% | 149.12% | 7.74% | - |
| Gross Profit | 314 | 250 | 199 | 166 | 177 | 120 | 30.78 | 6.95 | -1.05 | 2.29 |
| Operating Income | 10.48 | 15.92 | -24.94 | -32.02 | 9.46 | -5.17 | -53.29 | -49.30 | -39.10 | -22.71 |
| Net Income | -11.02 | -0.47 | -42.61 | -37.95 | 1.86 | -13.72 | -63.91 | -52.28 | -43.33 | -27.15 |
| Shares Outstanding | 41.51 | 40.91 | 39.81 | 37.24 | 36.54 | 35.30 | 33.18 | 30.33 | 16.44 | 0.57 |
| Earnings Per Share | -0.27 | -0.01 | -1.07 | -1.02 | 0.04 | -0.39 | -1.93 | -1.72 | -2.64 | -47.29 |
| Operating Cash Flow | 70.52 | 48.87 | 17.79 | 33.45 | 28.02 | 26.56 | -43.84 | -70.13 | -31.00 | -24.88 |
| Capital Expenditures | -10.16 | -14.51 | -19.27 | -24.71 | -40.30 | -22.98 | -12.17 | -18.26 | -6.15 | -6.77 |
| Free Cash Flow | 60.36 | 34.36 | -1.48 | 8.74 | -12.27 | 3.58 | -56.01 | -88.39 | -37.15 | -31.65 |
| Cash & Equivalents | 292 | 383 | 311 | 173 | 159 | 158 | 73.79 | 42.57 | 77.45 | 27.45 |
| Total Debt | 352 | 291 | 276 | 109 | 104 | 103 | 98.96 | 25.19 | 25.58 | 74.85 |
| Net Cash / Debt | -59.97 | 92.52 | 34.85 | 63.86 | 54.93 | 55.07 | -25.18 | 17.38 | 51.88 | -47.40 |
| Assets | 831 | 689 | 628 | 391 | 388 | 326 | 170 | 112 | 113 | 66.56 |
| Liabilities | 476 | 368 | 349 | 172 | 169 | 155 | 129 | 46.20 | 65.22 | 115 |
| Book Value | 355 | 321 | 279 | 219 | 218 | 171 | 41.25 | 65.86 | 48.27 | -48.38 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Pacira Biosciences, Inc. |
| Country |
United States |
| Employees |
606 |
| CEO |
David M. Stack |
Stock Information
| Ticker Symbol |
PCRX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: PCRX |
| IPO Date |
February 3, 2011 |
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.